Rucaparib was tested in a phase II trial in 16 germline BRCA1 (n= 12)/BRCA2 (n = 4) mutant pancreatic adenocarcinoma patients and 3 additional patients with somatic BRCA2 mutations who had received one or two chemotherapy lines [58]. Here, BRCA1 is linked to pancreatic adenocarcinoma.